Based on the anchor-based and distribution-based methods, the MCID is a 4-point difference on the FAS. This MCID can be used in the follow-up of fatigue (FAS) in clinical trials and in the management of individual sarcoidosis cases.

This review illustrates the importance of fatigue as an under-recognized complication of sarcoidosis. It further emphasizes the need for longitudinal prospective studies to better define sarcoidosis fatigue, explore its impact on quality of life, define aggravating or alleviating factors and evaluate new potential treatment strategies.

What is already known on this subject? Fatigue is a frequently reported symptom in sarcoidosis. Symptoms such as depressive symptoms and anxiety are also prevalent in sarcoidosis. However, the relationships between these symptoms are still unclear and require more research. What does this study add? This paper shows that fatigue is often accompanied by depressive symptoms and anxiety, although these symptoms are not fully overlapping. In addition, depressive symptoms and anxiety predict fatigue after follow-up. Fatigue, depressive symptoms and anxiety are most strongly correlated in patients with All Day Fatigue, which indicate that these patients may benefit from psychological interventions in the management of fatigue.